[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [<sup>68</sup>Ga]Ga-PSMA-11 has been approved in the United States by t...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/8/713 |
id |
doaj-049d758789974a98b3bef9a7bd2564c4 |
---|---|
record_format |
Article |
spelling |
doaj-049d758789974a98b3bef9a7bd2564c42021-08-26T14:12:06ZengMDPI AGPharmaceuticals1424-82472021-07-011471371310.3390/ph14080713[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate CancerUte Hennrich0Matthias Eder1German Cancer Research Center (DKFZ), Division of Radiology, 69120 Heidelberg, GermanyDivision of Radiopharmaceutical Development, German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), 69120 Heidelberg, GermanyFor the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [<sup>68</sup>Ga]Ga-PSMA-11 has been approved in the United States by the Food and Drug Administration (FDA) as the first <sup>68</sup>Ga-radiopharmaceutical for the PET imaging of PSMA-positive prostate cancer in 2020. This radiopharmaceutical combines the peptidomimetic Glu-NH-CO-NH-Lys(Ahx)-HBED-CC with the radionuclide <sup>68</sup>Ga, enabling specific imaging of tumor cells expressing PSMA. Such a targeting approach may also be used for therapy planning as well as potentially for the evaluation of treatment response.https://www.mdpi.com/1424-8247/14/8/713[<sup>68</sup>Ga]Ga-PSMA-11PSMAprostate cancertheranosticspositron emission tomography (PET) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ute Hennrich Matthias Eder |
spellingShingle |
Ute Hennrich Matthias Eder [<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer Pharmaceuticals [<sup>68</sup>Ga]Ga-PSMA-11 PSMA prostate cancer theranostics positron emission tomography (PET) |
author_facet |
Ute Hennrich Matthias Eder |
author_sort |
Ute Hennrich |
title |
[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer |
title_short |
[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer |
title_full |
[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer |
title_fullStr |
[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer |
title_full_unstemmed |
[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer |
title_sort |
[<sup>68</sup>ga]ga-psma-11: the first fda-approved <sup>68</sup>ga-radiopharmaceutical for pet imaging of prostate cancer |
publisher |
MDPI AG |
series |
Pharmaceuticals |
issn |
1424-8247 |
publishDate |
2021-07-01 |
description |
For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [<sup>68</sup>Ga]Ga-PSMA-11 has been approved in the United States by the Food and Drug Administration (FDA) as the first <sup>68</sup>Ga-radiopharmaceutical for the PET imaging of PSMA-positive prostate cancer in 2020. This radiopharmaceutical combines the peptidomimetic Glu-NH-CO-NH-Lys(Ahx)-HBED-CC with the radionuclide <sup>68</sup>Ga, enabling specific imaging of tumor cells expressing PSMA. Such a targeting approach may also be used for therapy planning as well as potentially for the evaluation of treatment response. |
topic |
[<sup>68</sup>Ga]Ga-PSMA-11 PSMA prostate cancer theranostics positron emission tomography (PET) |
url |
https://www.mdpi.com/1424-8247/14/8/713 |
work_keys_str_mv |
AT utehennrich sup68supgagapsma11thefirstfdaapprovedsup68supgaradiopharmaceuticalforpetimagingofprostatecancer AT matthiaseder sup68supgagapsma11thefirstfdaapprovedsup68supgaradiopharmaceuticalforpetimagingofprostatecancer |
_version_ |
1721190698480304128 |